Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Catherine Ellis(GlaxoSmithKline (United States))

Breast Cancer Research

July 23, 2014

10.1186/s13058-014-0405-y

Cited by 31

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

|Annals of Oncology|2020|1.4k

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

|Annals of Oncology|2021|799

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

|Annals of Oncology|2021|724